[1] Yu P, Zhou D, Liao W, et al. An investigation of the
characteristics of outpatients with epilepsy and
antiepileptic drug utilization in a multicenter
cross‑sectional study in China[J]. Epilepsy Behav, 2017,
69: 126‑132. DOI: 10.1016/j.yebeh.2016.09.021.
[2] Cascino GD. When drugs and surgery don′t work[J].
Epilepsia, 2008, 49 Suppl 9: 79‑84. DOI: 10.1111/
j.1528‑1167.2008.01930.x.
[3] Fisher RS, Cross JH, French JA, et al. Operational
classification of seizure types by the International League
Against Epilepsy: Position Paper of the ILAE Commission
for Classification and Terminology[J]. Epilepsia, 2017,
58(4): 522‑530. DOI: 10.1111/epi.13670.
[4] Scheffer IE, Berkovic S, Capovilla G, et al. ILAE
classification of the epilepsies: Position paper of the ILAE
Commission for Classification and Terminology[J].
Epilepsia, 2017, 58(4): 512‑521. DOI: 10.1111/epi.13709.
[5] 中国抗癫痫协会. 临床诊疗指南: 癫痫病分册[M]. 北京: 人
民卫生出版社, 2015.
China Association Against Epilepsy. Clinical diagnosis and
treatment guideline: epilepsy division[M]. Beijing:
People's Medical Publishing House, 2015.
[6] Loddenkemper T, Kotagal P. Lateralizing signs during
seizures in focal epilepsy[J]. Epilepsy Behav, 2005, 7(1):
1‑17. DOI: 10.1016/j.yebeh.2005.04.004.
[7] Baker J, Savage S, Milton F, et al. The syndrome of
transient epileptic amnesia: a combined series of 115
cases and literature review[J]. Brain Commun, 2021, 3(2):
fcab038. DOI: 10.1093/braincomms/fcab038.
[8] Barba C, Rheims S, Minotti L, et al. Temporal plus epilepsy
is a major determinant of temporal lobe surgery failures
[J].Brain,2016,139(Pt2):444‑451.DOI:10.1093/brain/awv372.
[9] Liu C, Qiao XZ, Wei ZH, et al. Molecular typing of familial
temporal lobe epilepsy[J]. World J Psychiatry, 2022,
12(1): 98‑107. DOI: 10.5498/wjp.v12.i1.98.
[10] McGonigal A. Frontal lobe seizures: overview and update
[J]. J Neurol, 2022, 269(6): 3363‑3371. DOI: 10.1007/
s00415‑021‑10949‑0.
[11] Tinuper P, Bisulli F. From nocturnal frontal lobe epilepsy
to sleep‑related hypermotor epilepsy: a 35‑year
diagnostic challenge[J]. Seizure, 2017, 44: 87‑92. DOI:
10.1016/j.seizure.2016.11.023.
[12] Chowdhury FA, Silva R, Whatley B, et al. Localisation in
focal epilepsy: a practical guide[J]. Pract Neurol, 2021,
21(6): 481‑491. DOI: 10.1136/practneurol‑2019‑002341.
[13] Isnard J, Guénot M, Sindou M, et al. Clinical manifestations
of insular lobe seizures: a stereo‑electroencephalographic
study[J]. Epilepsia, 2004, 45(9): 1079‑1090. DOI: 10.1111/
j.0013‑9580.2004.68903.x.
[14] Ryvlin P, Nguyen DK. Insular seizures and epilepsies: ictal
semiology and minimal invasive surgery[J]. Curr Opin
Neurol, 2021, 34(2): 153‑165. DOI: 10.1097/WCO.
0000000000000907.
[15] Nunes VD, Sawyer L, Neilson J, et al. Diagnosis and
management of the epilepsies in adults and children:
summary of updated NICE guidance[J]. BMJ, 2012, 344:
e281. DOI: 10.1136/bmj.e281.
[16] Rosenow F,Klein KM,Hamer HM.Non‑invasive EEG evaluation
in epilepsy diagnosis[J]. Expert Rev Neurother, 2015, 15(4):
425‑444.DOI:10.1586/14737175.2015.1025382.
[17] Bouma HK, Labos C, Gore GC, et al. The diagnostic
accuracy of routine electroencephalography after a first
unprovoked seizure[J]. Eur J Neurol, 2016, 23(3):
455‑463. DOI: 10.1111/ene.12739.
[18] Mullin JP, Shriver M, Alomar S, et al. Is SEEG safe? A systematic
review and meta‑analysis of stereo‑electroencephalography‑
related complications[J]. Epilepsia, 2016, 57(3): 386‑401.
DOI: 10.1111/epi.13298.
[19] Toth M, Papp KS, Gede N, et al. Surgical outcomes related
to invasive EEG monitoring with subdural grids or depth
electrodes in adults: a systematic review and
meta‑analysis[J]. Seizure, 2019, 70: 12‑19. DOI: 10.1016/j.
seizure.2019.06.022.
[20] Wellmer J, Quesada CM, Rothe L, et al. Proposal for a
magnetic resonance imaging protocol for the detection of
epileptogenic lesions at early outpatient stages[J]. Epilepsia,
2013, 54(11): 1977‑1987. DOI: 10.1111/epi.12375.
[21] Bernasconi A, Cendes F, Theodore WH, et al.
Recommendations for the use of structural magnetic
resonance imaging in the care of patients with epilepsy: a
consensus report from the International League Against
Epilepsy Neuroimaging Task Force[J]. Epilepsia, 2019,
60(6): 1054‑1068. DOI: 10.1111/epi.15612.
[22] Steinbrenner M, Duncan JS, Dickson J, et al. Utility of 18F‑fluorodeoxyglucose positron emission tomography in
presurgical evaluation of patients with epilepsy: a
multicenter study[J]. Epilepsia, 2022, 63(5): 1238‑1252.
DOI: 10.1111/epi.17194.
[23] Tan Z, Long X, Tian F, et al. Alterations in brain
metabolites in patients with epilepsy with impaired
consciousness: a case‑control study of interictal
multivoxel (1)H‑MRS findings[J]. AJNR Am J Neuroradiol,
2019, 40(2): 245‑252. DOI: 10.3174/ajnr.A5944.
[24] Zhang CH, Lu Y, Brinkmann B, et al. Lateralization and
localization of epilepsy related hemodynamic foci using
presurgical fMRI[J]. Clin Neurophysiol, 2015, 126(1):
27‑38. DOI: 10.1016/j.clinph.2014.04.011.
[25] Bagshaw AP, Kobayashi E, Dubeau F, et al.
Correspondence between EEG‑fMRI and EEG dipole localisation of interictal discharges in focal epilepsy[J].
Neuroimage,2006,30(2):417‑425.DOI:10.1016/j.neuroimage.2005.
09.033.
[26] O′Brien TJ, So EL, Mullan BP, et al. Subtraction ictal SPECT
co‑registered to MRI improves clinical usefulness of
SPECT in localizing the surgical seizure focus[J].
Neurology, 1998, 50(2): 445‑454.DOI: 10.1212/wnl.50.2.445.
[27] Kazemi NJ, Worrell GA, Stead SM, et al. Ictal SPECT
statistical parametric mapping in temporal lobe epilepsy
surgery[J]. Neurology, 2010, 74(1): 70‑76. DOI: 10.1212/
WNL.0b013e3181c7da20.
[28] Stefan H, Scheler G, Hummel C, et al.
Magnetoencephalography (MEG) predicts focal
epileptogenicity in cavernomas[J]. J Neurol Neurosurg
Psychiatry, 2004, 75(9): 1309‑1313. DOI: 10.1136/
jnnp.2003.021972.
[29] Brændholt M, Jensen M. Evidence from meta‑analysis
supports ictal magnetoencephalographic source imaging
as an accurate method in presurgery evaluation of
patients with drug‑resistant epilepsy[J]. Clin EEG
Neurosci, 2020, 51(6): 403‑411. DOI: 10.1177/
1550059420921534.
[30] Gavvala JR, Schuele SU. New‑onset seizure in adults and
adolescents: a review[J]. JAMA, 2016, 316(24):
2657‑2668. DOI: 10.1001/jama.2016.18625.
[31] Dibbens LM, de Vries B, Donatello S, et al. Mutations in
DEPDC5 cause familial focal epilepsy with variable foci[J].
Nat Genet, 2013, 45(5): 546‑551. DOI: 10.1038/ng.2599.
[32] Hill CE, Lin CC, Terman SW, et al. Definitions of
drug‑resistant epilepsy for administrative claims data
research[J]. Neurology, 2021, 97(13): e1343‑e1350. DOI:
10.1212/WNL.0000000000012514.
[33] Löscher W, Schmidt D. Modern antiepileptic drug
development has failed to deliver: ways out of the current
dilemma[J]. Epilepsia, 2011, 52(4): 657‑678. DOI: 10.1111/
j.1528‑1167.2011.03024.x.
[34] Marson AG, Al‑Kharusi AM, Alwaidh M, et al. The SANAD
study of effectiveness of carbamazepine, gabapentin,
lamotrigine, oxcarbazepine, or topiramate for treatment
of partial epilepsy: an unblinded randomised controlled
trial[J]. Lancet, 2007, 369(9566): 1000‑1015. DOI: 10.1016/
S0140‑6736(07)60460‑7.
[35] Marson A, Burnside G, Appleton R, et al. The SANAD Ⅱ
study of the effectiveness and cost‑effectiveness of
valproate versus levetiracetam for newly diagnosed
generalised and unclassifiable epilepsy: an open‑label,
non‑inferiority, multicentre, phase 4, randomised
controlled trial[J]. Lancet, 2021, 397(10282): 1375‑1386.
DOI: 10.1016/S0140‑6736(21)00246‑4.
[36] Campos MS, Ayres LR, Morelo MR, et al. Efficacy and
tolerability of antiepileptic drugs in patients with focal
epilepsy: systematic review and network meta‑analyses
[J].Pharmacotherapy,2016,36(12):1255‑1271.DOI:10.1002/
phar.1855.
[37] Iyer A, Marson A. Pharmacotherapy of focal epilepsy[J].
Expert Opin Pharmacother, 2014, 15(11): 1543‑1551.
DOI: 10.1517/14656566.2014.922544.
[38] Ji L, Chen Y, Mao Z, et al. Efficacy and tolerability of
lamotrigine in the treatment of focal epilepsy among
children and adolescents: a meta‑analysis[J]. Transl
Pediatr, 2021, 10(4): 807‑818. DOI: 10.21037/tp‑20‑379.
[39] Glauser T, Ben‑Menachem E, Bourgeois B, et al. Updated
ILAE evidence review of antiepileptic drug efficacy and
effectiveness as initial monotherapy for epileptic seizures
and syndromes[J]. Epilepsia, 2013, 54(3): 551‑563. DOI:
10.1111/epi.12074.
[40] Kanner AM, Ashman E, Gloss D, et al. Practice guideline
update summary: efficacy and tolerability of the new
antiepileptic drugs Ⅰ: treatment of new‑onset epilepsy:
report of the guideline development, dissemination, and
implementation subcommittee of the American Academy
of Neurology and the American Epilepsy Society[J].
Neurology, 2018, 91(2): 74‑81. DOI: 10.1212/WNL.
0000000000005755.
[41] Kim JH, Lee SK, Loesch C, et al. Comparison of
levetiracetam and oxcarbazepine monotherapy among
Korean patients with newly diagnosed focal epilepsy: a
long‑term, randomized, open‑label trial[J]. Epilepsia,
2017, 58(4): e70‑e74. DOI: 10.1111/epi.13707.
[42] Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an
unblinded, randomised, two parallel‑group, stratified trial
comparing the effectiveness of levetiracetam with
controlled‑release carbamazepine and extended‑release
sodium valproate as monotherapy in patients with newly
diagnosed epilepsy[J]. J Neurol Neurosurg Psychiatry,
2013, 84(10): 1138‑1147. DOI: 10.1136/jnnp‑2011‑300376.
[43] Ben‑Menachem E, Biton V, Jatuzis D, et al. Efficacy and
safety of oral lacosamide as adjunctive therapy in adults
with partial‑onset seizures[J]. Epilepsia, 2007, 48(7):
1308‑1317. DOI: 10.1111/j.1528‑1167.2007.01188.x.
[44] Inoue Y, Liao W, Wang X, et al. Safety and efficacy of
adjunctive lacosamide in Chinese and Japanese adults
with epilepsy and focal seizures: a long‑term, open‑label
extension of a randomized, controlled trial[J]. Epilepsy
Res, 2021, 176: 106705. DOI: 10.1016/j.eplepsyres.2021.
106705.
[45] French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of
adjunctive perampanel in patients with refractory
partial‑onset seizures: results of randomized global phase
Ⅲ study 305[J]. Epilepsia, 2013, 54(1): 117‑125. DOI:
10.1111/j.1528‑1167.2012.03638.x.
[46] French JA, Krauss GL, Biton V, et al. Adjunctive
perampanel for refractory partial‑onset seizures:
randomized phase Ⅲ study 304[J]. Neurology, 2012,
79(6): 589‑596. DOI: 10.1212/WNL.0b013e3182635735.
[47] Krauss GL, Serratosa JM, Villanueva V, et al. Randomized
phase Ⅲ study 306: adjunctive perampanel for refractory
partial‑onset seizures[J]. Neurology, 2012, 78(18):
1408‑1415. DOI: 10.1212/WNL.0b013e318254473a.
[48] National Institute for Health and Care Excellence. The
epilepsies: evidence update february[M/OL]. London:
National Institute for Health and Care Excellence (NICE),
2014[2021‑09‑12].https://www.ncbi.nlm.nih.gov/books/
NBK552057/.
[49] Viteva E, Zahariev Z. Topiramate Effectiveness as add‑on
therapy in Bulgarian patients with drug‑resistant epilepsy
[J]. Folia Med (Plovdiv), 2020, 62(4): 712‑722. DOI:
10.3897/folmed.62.e50175.
[50] Brodie MJ, Duncan R, Vespignani H, et al. Dose‑dependent
safety and efficacy of zonisamide: a randomized,
double‑blind, placebo‑controlled study in patients with
refractory partial seizures[J]. Epilepsia, 2005, 46(1):31‑41. DOI: 10.1111/j.0013‑9580.2005.14704.x.
[51] Faught E, Ayala R, Montouris GG, et al. Randomized
controlled trial of zonisamide for the treatment of
refractory partial‑onset seizures[J]. Neurology, 2001,
57(10): 1774‑1779. DOI: 10.1212/wnl.57.10.1774.
[52] Trinka E, Ben‑Menachem E, Kowacs PA, et al. Efficacy and
safety of eslicarbazepine acetate versus controlled‑release
carbamazepine monotherapy in newly diagnosed
epilepsy: a phase Ⅲ double‑blind, randomized,
parallel‑group, multicenter study[J]. Epilepsia, 2018,
59(2): 479‑491. DOI: 10.1111/epi.13993.
[53] Sperling MR, Abou‑Khalil B, Harvey J, et al.
Eslicarbazepine acetate as adjunctive therapy in patients
with uncontrolled partial‑onset seizures: Results of a
phase Ⅲ , double‑blind, randomized, placebo‑controlled
trial[J]. Epilepsia, 2015, 56(2): 244‑253. DOI: 10.1111/
epi.12894.
[54] O′Brien TJ, Borghs S, He QJ, et al. Long‑term safety,
efficacy, and quality of life outcomes with adjunctive
brivaracetam treatment at individualized doses in
patients with epilepsy: an up to 11‑year, open‑label,
follow‑up trial[J]. Epilepsia, 2020, 61(4): 636‑646. DOI:
10.1111/epi.16484.
[55] Picot MC, Jaussent A, Neveu D, et al. Cost‑effectiveness
analysis of epilepsy surgery in a controlled cohort of
adult patients with intractable partial epilepsy: a 5‑year
follow‑up study[J]. Epilepsia, 2016, 57(10): 1669‑1679.
DOI: 10.1111/epi.13492.
[56] Engel J, McDermott MP, Wiebe S, et al. Early surgical
therapy for drug‑resistant temporal lobe epilepsy: a
randomized trial[J]. JAMA, 2012, 307(9): 922‑930. DOI:
10.1001/jama.2012.220.
[57] Wiebe S, Blume WT, Girvin JP, et al. A randomized,
controlled trial of surgery for temporal‑lobe epilepsy[J]. N
Engl J Med, 2001, 345(5): 311‑318. DOI: 10.1056/
NEJM200108023450501.
[58] Schmidt D, Stavem K. Long‑term seizure outcome of surgery
versus no surgery for drug‑resistant partial epilepsy: a
review of controlled studies[J]. Epilepsia, 2009, 50(6):
1301‑1309. DOI: 10.1111/j.1528‑1167.2008.01997.x.
[59] Fisher RS, Handforth A. Reassessment: vagus nerve
stimulation for epilepsy: a report of the Therapeutics and
Technology Assessment Subcommittee of the American
Academy of Neurology[J]. Neurology, 1999, 53(4):
666‑669. DOI: 10.1212/wnl.53.4.666.
[60] Morris GL, Gloss D, Buchhalter J, et al. Evidence‑based
guideline update: vagus nerve stimulation for the
treatment of epilepsy: report of the Guideline
Development Subcommittee of the American Academy of
Neurology[J]. Neurology, 2013, 81(16): 1453‑1459. DOI:
10.1212/WNL.0b013e3182a393d1.
[61] Bergey GK, Morrell MJ, Mizrahi EM, et al. Long‑term
treatment with responsive brain stimulation in adults
with refractory partial seizures[J]. Neurology, 2015,
84(8): 810‑817. DOI: 10.1212/WNL.0000000000001280.
[62] Nair DR, Laxer KD, Weber PB, et al. Nine‑year prospective
efficacy and safety of brain‑responsive neurostimulation
for focal epilepsy[J]. Neurology, 2020, 95(9):
e1244‑e1256. DOI: 10.1212/WNL.0000000000010154.
[63] Fisher R, Salanova V, Witt T, et al. Electrical stimulation of
the anterior nucleus of thalamus for treatment of
refractory epilepsy[J]. Epilepsia, 2010, 51(5): 899‑908.
DOI: 10.1111/j.1528‑1167.2010.02536.x.
[64] Salanova V, Witt T, Worth R, et al. Long‑term efficacy and
safety of thalamic stimulation for drug‑resistant partial
epilepsy[J]. Neurology, 2015, 84(10): 1017‑1025. DOI:
10.1212/WNL.0000000000001334.
[65] Salanova V, Sperling MR, Gross RE, et al. The SANTÉ study
at 10 years of follow‑up: effectiveness, safety, and sudden
unexpected death in epilepsy[J]. Epilepsia, 2021, 62(6):
1306‑1317. DOI: 10.1111/epi.16895.
[66] Hsu WY, Cheng CH, Lin MW, et al. Antiepileptic effects of
low frequency repetitive transcranial magnetic
stimulation: a meta‑analysis[J]. Epilepsy Res, 2011, 96(3):
231‑240. DOI: 10.1016/j.eplepsyres.2011.06.002.
[67] Sun W, Mao W, Meng X, et al. Low‑frequency repetitive
transcranial magnetic stimulation for the treatment of
refractory partial epilepsy: a controlled clinical study[J].
Epilepsia, 2012, 53(10): 1782‑1789. DOI: 10.1111/j.1528‑
1167.2012.03626.x.
[68] Fregni F, Thome‑Souza S, Nitsche MA, et al. A controlled
clinical trial of cathodal DC polarization in patients with
refractory epilepsy[J]. Epilepsia, 2006, 47(2): 335‑342.
DOI: 10.1111/j.1528‑1167.2006.00426.x.
[69] San‑Juan D, Espinoza López DA, Vázquez Gregorio R, et al.
Transcranial direct current stimulation in mesial
temporal lobe epilepsy and hippocampal sclerosis[J].
Brain Stimul, 2017, 10(1): 28‑35. DOI: 10.1016/j.brs.2016.
08.013.
[70] Bauer S, Baier H, Baumgartner C, et al. Transcutaneous
vagus nerve stimulation (tVNS) for treatment of
drug‑resistant epilepsy: a randomized, double‑blind
clinical trial (cMPsE02) [J]. Brain Stimul, 2016, 9(3):
356‑363. DOI: 10.1016/j.brs.2015.11.003.
